Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial

被引:133
作者
Bousquet, J [1 ]
Lund, VJ
van Cauwenberge, P
Bremard-Oury, C
Mounedji, N
Stevens, MT
El-Akkad, T
机构
[1] Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France
[2] Ghent Univ Hosp, B-9000 Ghent, Belgium
[3] UCL, Sch Med, London W1N 8AA, England
[4] Lab Aventis, Paris, France
[5] EmStat Ltd, Leicester, Leics, England
[6] Aventis Pharma, Bridgewater, NJ USA
关键词
histamine H-1 antagonists; intranasal administration; practice guidelines; quality of life; seasonal allergic rhinitis;
D O I
10.1034/j.1398-9995.2003.00076.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Allergic rhinitis is a common disease altering quality of life. Its treatment is well established and guidelines have been proposed. However, their efficacy has never been tested. The aim of the study was to validate the guidelines of the International Consensus on Rhinitis in the treatment of seasonal allergic rhinitis. Methods: A multicenter, multinational, open label, parallel, randomized study compared two therapeutic strategies in seasonal allergic rhinitis during a 3-week treatment. General practitioners were randomized into two groups. In the first group of 224 patients, doctors followed guidelines from the International Consensus on Rhinitis. Depending on the severity of nasal and ocular symptoms defined using visual analogue scales, patients received ebastine (an oral antihistamine), triamcinolone acetonide (a topical corticosteroid) and/or ophthalmic nedocromil sodium (a topical ocular cromone). In the second group of 241 patients, general practitioners had a free choice of treatment. The primary efficacy end points were quality of life measured using the standardized rhinoconjunctivitis quality of life questionnaire (RQLQ) and the symptom-medication scores assessed daily with an electronic dairy system. Results: Adjusted mean total symptom scores over 21 days were 4.93 in the guidelines strategy group compared with 7.48 in the free-choice treatment group (P = 0.0001). Mean total scores in the RQLQ decreased by 2.19 in the guidelines group compared with a decrease of 1.79 in the free-choice treatment group (P = 0.0001). At 21 days, the least square mean difference in improvement in overall scores for RQLQ in the guidelines group compared with the free-choice treatment group was 0.53, which was greater than the minimal important difference. Conclusions: Patients with seasonal allergic rhinitis often present severe symptoms which are not well recognized or controlled by physicians using their own criteria of severity and treatment. Using a simple method for the evaluation of the severity and a simple therapeutic scheme based on International Guidelines, patients with seasonal allergic rhinitis presented a significant improvement by comparison with those receiving a non-standardized treatment.
引用
收藏
页码:733 / 741
页数:9
相关论文
共 39 条
  • [1] Ahluwalia P, 1999, INVEST OPHTH VIS SCI, V40, pS771
  • [2] COMPARATIVE THERAPEUTIC STUDIES WITH TILAVIST
    ALEXANDER, M
    [J]. ALLERGY, 1995, 50 (21) : 23 - 29
  • [3] A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND TOLERABILITY OF EBASTINE AGAINST HAYFEVER IN GENERAL-PRACTICE PATIENTS
    ANKIER, SI
    WARRINGTON, SJ
    [J]. JOURNAL OF INTERNAL MEDICINE, 1989, 226 (06) : 453 - 458
  • [4] Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis
    Bernstein, DI
    Creticos, PS
    Busse, WW
    Cohen, R
    Graft, DF
    Howland, WC
    Lumry, WR
    Pedinoff, AJ
    Ratner, PH
    Lim, J
    Stokes, A
    McNally, C
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (03) : 749 - 755
  • [5] Bray GA, 1999, DIABETES CARE, V22, P623
  • [6] Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis
    Ciprandi, G
    Canonica, WG
    Grosclaude, M
    Ostinelli, J
    Brazzola, GG
    Bousquet, J
    [J]. ALLERGY, 2002, 57 (07) : 586 - 591
  • [7] A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis
    Day, JH
    Buckeridge, DL
    Clark, RH
    Briscoe, MP
    Phillips, R
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (05) : 1050 - 1057
  • [8] Joint task force algorithm and annotations for diagnosis and management of rhinitis
    Dykewicz, MS
    Fineman, S
    Nicklas, R
    Lee, R
    Blessing-Moore, J
    Li, JT
    Bernstein, IL
    Berger, W
    Spector, S
    Schuller, D
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (05) : 469 - 473
  • [9] Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis
    Dykewicz, MS
    Fineman, S
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (05) : 463 - 468
  • [10] Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation
    Guyatt, GH
    King, DR
    Feeny, DH
    Stubbing, D
    Goldstein, RS
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (03) : 187 - 192